Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide and 3BNC117 Maintenance in HIV-1
NCT03719664Phase 2Unknown
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
A Phase 2 trial of albuvirtide, Teropavimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Frontier Biotechnologies Inc.. Status: unknown.
02
Drugs
albuvirtideTeropavimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03719664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719664.